
Advancing a New Era of CNS Therapeutics
Utilizing our unique di si-RNA platform, Atalanta Therapeutics is dedicated to finding solutions for intractable diseases of the central nervous system. Our pipeline is composed of programs addressing diseases with significant unmet need with the potential to improve the lives of millions of patients around the world.
Epilepsy
KCNT1 (ATL-201)
Genetic Epilepsy
KCNT1 (ATL-201) progress: 55%
Huntington’s Disease
Pan HD (ATL-101)
Huntington’s Disease
Pan HD (ATL-101) progress: 50%
MSH3
Huntington’s Disease
MSH3 progress: 25%
SNP Selective
Huntington’s Disease
SNP Selective progress: 25%
Alzheimer’s Disease
CD33
Alzheimer’s Disease
CD33 progress: 25%
APOE
Alzheimer’s Disease
APOE progress: 25%
Pain
SCN9A (ATL-301)
Trigeminal Neuralgia
SCN9A (ATL-301) progress: 30%
CNS Disorders
Undisclosed
Multiple Targets
Undisclosed progress: 25%


CNS Disorders
Undisclosed
Multiple Targets
Undisclosed progress: 35%

